NGEN

NervGen Pharma Corp. Common stock

1.33

USD

-0.06

-4.66%

Nov 10, 15:59 UTC -5

Closed

After-Market

1.33

0.00

+0.38%

NervGen Pharma Corp. Common stock (NGEN) Earnings

NGEN Earnings Reports

Positive Surprise Ratio

NGEN beat 1 of 1 last estimates.

100%

Next Report

In 2 Days

Date of Next Report

Nov 12, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$0.05

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q3 25 (Revenue/ EPS)

-100.00%

-16.67%

NervGen Pharma Corp. Common stock earnings per share and revenue

On Aug 13, 2026, NGEN reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.05 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.

Looking ahead to Q3 26, -- analysts forecast an EPS of -0.05 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were NervGen Pharma Corp. Common stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, NervGen Pharma Corp. Common stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.

How did the market react to NervGen Pharma Corp. Common stock's Q2 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is NervGen Pharma Corp. Common stock expected to report next?

The next earning report is scheduled for Nov 12, 2026.

What are the forecasts for NervGen Pharma Corp. Common stock's next earnings report?

Based on -- analysts, NervGen Pharma Corp. Common stock is expected to report EPS of -$0.05 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.